Lack of carboxyl-terminal tyrosine distinguishes the B(*)2706-bound peptide repertoire from those of B(*)2704 and other HLA-B27 subtypes associated with ankylosing spondylitis

Tissue Antigens

Volumn 49, Issue 3 I, 1997, Pages 215-221

  Garcia F ^a   Marina, A ^a   Lopez De Castro J A ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Ankylosing spondylitis; B(*)2704; B(*)2706; HLA B27; Peptide motifs

Indexed keywords

AROMATIC AMINO ACID; HLA B27 ANTIGEN; LIGAND; PEPTIDE; TYROSINE;

AMINO ACID SUBSTITUTION; ANKYLOSING SPONDYLITIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0030952980     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1997.tb02741.x     Document Type: Article

References (27)

1. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973: 1: 904-7.
2. Burmester GR, Daser A, Kamradt T et al. Immunology of reactive arthritides. Annu Rev Immunol 1995: 13: 229-50.
3. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990: 63: 1099-112.
4. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993: 342: 646-50.
5. Breur-Vriesendorp BS, Dekker Saeys AJ, Ivanyi P. Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: the disease is associated with a common determinant of the various B27 molecules. Ann Rheum Dis 1987: 46: 353-6.
6. Lopez-Larrea C, Sujirachato K, Mehra NK et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens 1995: 45: 169-76.
7. D'Amato M, Fiorillo MT, Carcassi C et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995: 25: 3199-201.
8. Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990: 11: 137-42.
9. Vega MA, Bragado R, Ivanyi P, Pelaez JL, Lopez de Castro JA. Molecular analysis of a functional subtype of HLA-B27. A possible evolutionary pathway for HLA-B27 polymorphism. J Immunol 1986: 137: 3557-65.
10. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992: 70: 1035-48.
11. Galocha B, Lamas JR, Villadangos JA, Albar JP, López de Castro JA. Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. Tissue Antigens 1996: 48: 509-18.
12. Benjamin RJ, Madrigal JA, Parharn P. Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 1991: 351: 74-7.
13. Calvo V, Rojo S, Lopez D, Galocha B, López de Castro JA. Structure and diversity of HLA-B27-specific T cell epitopes. Analysis with site-directed mutants mimicking HLA-B27 subtype polymorphism. J Immunol 1990: 144: 4038-45.
14. Barnstable CJ, Bodmer WF, Brown G et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens. New tools for genetic analysis. Cell 1978: 14: 9-20.
15. Villadangos JA, Galocha B, Garcia F, Albar JP, López de Castro JA. Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703. Eur J Immunol 1995: 25: 2370-7.
16. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991: 351: 290-6.
17. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med 1993: 178: 879-87.
18. Rudwaleit M, Bowness P, Wordsworth P. The nucleotide sequence of HLA-B*2704 reveals a new amino acid substitution in exon 4 which is also present in HLA-B*2706. Immunogenetics 1996: 43: 160-2.
19. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 1991: 353: 326-9
20. Rotzschke O, Falk K, Stevanovic S, Gnau V, Jung G, Rammensee HG. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 1994: 39: 74-7.
21. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995: 41: 178-228.
22. Huczko EL, Bodnar WM, Benjamin D et al. Characteristics of endogenous peptides eluted from the class I MHC molecule HLA-B7 determined by mass spectrometry and computer modeling. J Immunol 1993: 151: 2572-87.
23. Fremont DH, Matsumura M, Stura EA, Peterson PA, Wilson IA. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 1992: 257: 919-27.
24. Smith KJ, Reid SW, Harlos K et al. Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53. Immunity 1996: 4: 215-28.
25. Rojo S, Garcia F, Villadangos JA, López de Castro JA. Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pocket B. J Exp Med 1993: 177: 613-20.
26. Del Porto P, D'Amato M, Fiorillo MT, Tuosto L, Piccolella E, Sorrentino R. Identification of a novel HLA-B27 subtype by restriction analysis of a cytotoxic gamma delta T cell clone. J Immunol 1994: 153: 3093-100.
27. Fiorillo MT, Greco G, Sorrentino R. The Asp116-His116 substitution in a novel HLA-B27 subtype influences the acceptance of the peptide C-terminal anchor. Immunogenetics 1995: 41: 38-41.